LCID
Lucid Group, Inc.
LCID has the edge over THRM overall, supported by stronger modeled upside and stronger valuation.
THRM
Gentherm Incorporated
THRM trails on the overall score without a compensating advantage in the available component scores.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
THRM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
THRM's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
THRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $28.79 | — |
| Cheap | 24x | $6.79 | -76% |
| Fair | 36x | $10.21 | -65% |
| Expensive | 62x | $17.38 | -40% |
| Current | 103x | $28.79 | — |
Historical ranges are pointers, not guarantees.
THRM's PE is in its expensive range at 103x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
THRM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for THRM, but weaker profitability. However, they disagree widely on these estimates.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
THRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +907% |
| Q3 2026 | $0.28 | -72% |
| Q2 2026 | $0.85 | -16% |
| Q1 2026 | $0.73 | -54% |
| Q4 2025 | $0.59 | -71% |
| Q3 2025 | $0.99 | -54% |
| Q2 2025 | $1.01 | -52% |
| Q1 2025 | $1.59 | +9.7% |
| Q4 2024 | $2.06 | +69% |
THRM has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over THRM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
THRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $405.1M | +4.7% |
| Q2 2026 | $416.2M | +11% |
| Q1 2026 | $393.7M | +11% |
| Q4 2025 | $382.8M | +8.5% |
| Q3 2025 | $386.9M | +4.1% |
| Q2 2025 | $375.1M | -0.2% |
| Q1 2025 | $353.9M | -0.6% |
| Q4 2024 | $352.9M | -3.8% |
THRM's revenue has grown year over year for five quarters in a row: $405M last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | -2.6 points |
| Q2 2026 | 2.6% | -3.8 points |
| Q1 2026 | 2.9% | -2 points |
| Q4 2025 | 4.6% | -2.1 points |
| Q3 2025 | 6.2% | -2.5 points |
| Q2 2025 | 6.4% | -2.4 points |
| Q1 2025 | 4.8% | -0.3 points |
| Q4 2024 | 6.7% | -1.9 points |
THRM has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
THRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.4M | -45% |
| Q2 2026 | -$1.2M | -103% |
| Q1 2026 | -$10.7M | +$17.5M |
| Q4 2025 | $6.7M | -51% |
| Q3 2025 | $46.5M | +75% |
| Q2 2025 | $36.2M | +104% |
| Q1 2025 | -$28.2M | -$6.6M |
| Q4 2024 | $13.6M | -52% |
THRM has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
THRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -382K shares |
| 1 year | -0.2% | -76K shares |
| 3 years | -7.6% | -2.5M shares |
| 5 years | -8.7% | -2.9M shares |
| Available history | -7.9% | -2.6M shares |
THRM has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $10M |
| Q1 2025 | — |
| Q4 2024 | $10M |
| Q3 2024 | $19.9M |
| Q4 2023 | $60M |
| Q3 2023 | $11.1M |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
THRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.5x | Very low |
THRM's net debt is less than a year of its operating earnings (EBITDA).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
THRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
THRM's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
THRM PE vs Consumer Cyclical Sector
| Metric | THRM | Sector median | Relative |
|---|---|---|---|
| PE | 103x | 18x | 471% above |
| PE % | 96 | 47 | 49 pts above |
THRM is trading at 103x earnings, a 471% premium to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
THRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.4 | 5.2% below |
| 20 week MA | $35.7 | 19% below |
| 50 week MA | $34.1 | 16% below |
| 100 week MA | $33.4 | 14% below |
| 200 week MA | $43.3 | 33% below |
THRM is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
THRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.3 | $66.0 | +49% |
| 2021 | $66.0 | $82.4 | +25% |
| 2022 | $82.4 | $63.8 | -23% |
| 2023 | $63.8 | $52.4 | -18% |
| 2024 | $52.4 | $39.0 | -25% |
| 2025 | $39.0 | $37.2 | -4.7% |
| 2026 YTD | $37.2 | $28.8 | -23% |
THRM has the edge over LCID on returns for 2026, with the stronger performance.